



0040-4039(94)E0787-X


Practical, Stereocontrolled Synthesis of 2-Functionalized-methyl-1 $\beta$ -methylcarbapenems

Shoichiro Uyeo\* and Hikaru Itani

Shionogi Research Laboratories, Shionogi &amp; Co., Ltd., Fukushima-ku, Osaka 553, Japan


**Abstract:** Reaction of acetoxy-azetidinone **4**, (*Z*)-crotylbromide **5** and Zn selectively gave **6**, which was converted to 1 $\beta$ -methyl-2-(hydroxymethyl)carbapenem **11**, a key intermediate in synthesis of antibiotic **2**, in high overall yield.

2-Functionalized-methyl-1 $\beta$ -methylcarbapenem antibiotics **11,2**, which can be clearly distinguished from conventional-type 1 $\beta$ -methylcarbapenems represented by meropenem (SM-7338) **3**, have recently attracted much attention because of their high therapeutic potential. In the course of our project to develop carbapenem antibiotics, we have found that 2-(*N*-methyl-4-pyridinio)thiomethyl derivative **2** showed excellent *in vivo* as well as *in vitro* activity against both Gram-positive and -negative bacteria **4**.



We report herein a highly stereocontrolled and practical synthesis of **2**, which allowed us to carry out further evaluation of this and related compounds as potential therapeutic agents.

The commercially available acetoxy-azetidinone **4**<sup>5</sup> was reacted with ethyl (*Z*)-2-(bromomethyl)-but-2-enoate **5**<sup>6</sup> (1.5 eq.) and Zn dust (1.5 eq.) in DMF at 25–32°C for 4 h. to give, after usual work-up and recrystallization, a single isomer **6** in 90% yield. The 1*S*,5*R* stereochemistry (carbapenem structure numbering) of **6** was proved by its successful conversion to the known derivatives **10** and **11** (*vide infra*). The 1*R* diastereoisomer, the only



other isomer which could be isolated for characterization, was detected by HPLC in less than 5% of the crude product. Reduction of **6** (DIBAL-toluene, -40 °C) followed by tritylation (TrCl-Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt) gave the protected allylic alcohol **7** in 78% yield, which on ozonolysis (CH<sub>2</sub>Cl<sub>2</sub>-MeOH, -70 °C, then Me<sub>2</sub>S, rt) provided the ketone **8** in 87% yield. The stable ylid **9** was then prepared by the standard procedure {1)HCOCO<sub>2</sub>PMB, cat. Et<sub>3</sub>N, THF, rt 2)SOCl<sub>2</sub>-lutidine, THF, -40°C 3)PPh<sub>3</sub>-lutidine, NaBr} in 75% yield. All the above intermediates including the ylid **9** are easy-to-purify crystalline materials which are suitable for large-scale synthetic operations. The two protective groups were removed by acid treatment (HCl-MeCN) and the primary OH group was selectively acetylated to give the monoacetoxy-ylid **10**. This synthesis of **10** is much more efficient and practical than our previous ones **7**, and **10** was converted to **11**, the key intermediate in the synthesis of the antibiotic **2**. The overall yield of **11** from the ylid **9** was 71%.

The application of this method to the preparation of various 1β-(functionalized-)alkylcarbapenems of this type is now being investigated in our laboratories <sup>8,9</sup>.

#### REFERENCES AND NOTES

1. Haruta, J.; Nishi, K.; Kikuchi, K.; Matsuda, S.; Tamura, Y.; Kita, Y. *Chem. Pharm. Bull.* **1989**, *37*, 2338.
2. (a) Schmitt, S. M.; Salzmann, T. N.; Shih, D. H.; Christensen, B. G.; *J. Antibiot.* **1988**, *41*, 780. (b) Salzmann, T. N.; DiNinno, F. P.; Greenlee, M. L.; Guthikonda, R. N.; Quesada, M. L.; Schmitt, S. M.; Herrmann, J. J.; Woods, M. F. "Recent Advances in the Chemistry of Beta-Lactam Antibiotics", Royal Society of Chemistry, Special Publication, 1989; Vol. 70, p 171. (c) Imuta, M.; Itani, H.; Ona, H.; Hamada, Y.; Uyeo, S.; Yoshida, T. *Chem. Pharm. Bull.* **1991**, *39*, 663.
3. Sunagawa, M.; Matsumura, H.; Inoue, T.; Fukasawa, M.; Kato, M. *J. Antibiot.* **1990**, *43*, 519.
4. Imuta, M.; Itani, H.; Ona, H.; Konoike, T.; Uyeo, S.; Kimura, Y.; Miwa, H.; Matsuura, S.; Yoshida, T. *Chem Pharm. Bull.* **1991**, *39*, 672.
5. This compound is available from Kanegafuchi Chemical Co., Ltd., Osaka, Japan.
6. Drewes, S. E.; Emslie, N. D. *J. Chem. Soc. Perkin Trans. I* **1982**, 2079. The purity of this compound was ca. 95% (200MHz NMR)
7. (a) Ref. 2 (c). (b) Uyeo, S.; Itani, H. *Tetrahedron Lett.* **1991**, *32*, 2143.
8. An alternative application: see Mori, M.; Oida, S. *Bio. Med. Chem. Lett.* **1993**, *3*, 2389.
9. Selected physical data: **6**; mp 92-93.5 °C. <sup>1</sup>H-NMR(200MHz CDCl<sub>3</sub>) δ: 0.06 (6H, s), 0.87 (9H, s), 1.14 (3H, d, *J*=6.2Hz), 1.15 (3H, d, *J*=7Hz), 1.31 (3H, t, *J*=7.2Hz), 2.83 - 2.86 (1H, m), 2.97 - 3.11 (1H, m), 3.76 (1H, dd, *J*=6Hz, 2.2Hz), 4.11 - 4.25 (1H, m), 4.22 (2H, q, *J*=7.2Hz), 5.63 (1H, s), 5.88 (1H, s), 6.31(1H, s). **7**; mp147-148 °C. <sup>1</sup>H-NMR(200MHz CDCl<sub>3</sub>) δ: 0.03 (6H, s), 0.83 (9H, s), 1.03 (3H, d, *J*=7Hz), 1.07 (3H, d, *J*=6.2Hz), 2.22 - 2.36 (1H, m), 2.69 (1H, dd, *J*=4.3Hz, 2.2Hz), 3.58(1H, dd, *J*=5.8Hz, 2.2Hz), 3.51 and 3.61 (2H, ABq, *J*=13Hz), 4.02- 4.14 (1H, m), 5.01 (1H, s), 5.41 (1H, s), 5.65(1H, s), 7.26 - 7.47(15H, m). **8** mp133-134 °C. <sup>1</sup>H-NMR(200MHz CDCl<sub>3</sub>) δ : 0.04 (3H, s), 0.06 (3H, s), 0.86 (9H, s), 1.09 (3H, d, *J*=7Hz), 1.15(3H, d, *J*=6.2Hz), 2.83 (1H, dd, *J*=5Hz, 2.2Hz), 3.09 - 3.22 (1H, m), 3.79 (1H, dd, *J*=4.4Hz, 2.2Hz), 3.84 (2H, s), 4.07 - 4.19 (1H, m), 5.75(1H, s), 7.26 - 7.46(1H, m). **9**; mp178-179 °C.

(Received in Japan 1 February 1994; accepted 11 April 1994)